We recently showed that high levels of B cell Activating Factor (BAFF) after allogeneic hematopoietic stem cell transplantation (HSCT) correlate with chronic GVHD development. BAFF promotes survival and differentiation of human BCR-activated (CD27+) B cells into Ig-secreting cells (ISC). To examine whether BAFF drives ISC in cGVHD, CD27+ peripheral B subsets and plasma BAFF levels were examined in 57 patients ≥ 12 months after HSCT. Significantly higher BAFF levels were found in active and inactive cGVHD groups compared to control patients with no cGVHD. Patients with cGVHD had a relative reduction in naive B cells compared to controls, resulting in a preponderance of CD27+ B cells (Table 1). Both pre-germinal center [pre-GC (IgD+)] and post-GC (IgDLo) subsets had significantly increased CD27+ in active cGVHD (Table 2). When BAFF levels were compared with cell number, only active disease patients had a positive correlation between BAFF and plasmablasts (r=+0.51, p-value=0.013), suggesting CD27+ post-GC B cells are highly BAFF-dependent in cGVHD. Active and inactive cGVHD patients had a positive correlation between BAFF and number of CD27+ pre-GC cells (r=+0.5, r=+0.49, respectively, p-value=0.02 each). In vitro analysis of these infrequent B subpopulations was accomplished using a large-volume lymphocyte donation from an untreated active cGVHD patient. Plasmablast and pre-GC purified populations had distinctly higher apoptotic rates attenuated in vitro by BAFF. CD27+ pre-GC B cells were induced by BAFF to differentiate into post-GC plasmablasts, indicating that survival and differentiation effects likely explain the correlations between BAFF and pre and post-GC CD27+ B subsets in patients. Increased BAFF levels in patients with inactive disease also correlated with lower total B (r=−0.59, p=0.003) and memory subset numbers (r=−0.57, p=0.005) suggesting that simultaneous B cell turnover and reconstitution may occur as disease becomes inactive. Thus, peripheral CD27+ B cells differentiate into potentially alloreactive ISC in presence of excess BAFF without need for further antigen stimulation. These results implicate BAFF and BCR-activated B cells in cGVHD and provide a rationale for therapeutic use of BAFF antagonists in this disease.
Median BAFF Levels & Relative Increase in CD27+ BCR-activated B cells in cGVHD
Disease Status & Median Time post-HSCT (months)
. | BAFF (ng/ml)
. | p-value vs. none
. | Naive B # (x 106
. | p-value vs. none
. | CD27 of B cells (%)
. | p-value vs. none
. |
---|
Active, n=22 (21 mo.) | 7.0 | 0.0003 | 79.8 | 0.0009 | 19.0 | 0.06 |
Inactive, n=23 (31mo.) | 5.5 | 0.02 | 99.1 | 0.0005 | 8.4 | 0.21 |
None, n=12 (27 mo.) | 3.0 | | 260.5 | | 6.1 | |
Healthy, n=33 (no HSCT) | 1.9 | 0.003 | 89.5 | 0.0004 | 27.3 | <0.0001 |
Disease Status & Median Time post-HSCT (months)
. | BAFF (ng/ml)
. | p-value vs. none
. | Naive B # (x 106
. | p-value vs. none
. | CD27 of B cells (%)
. | p-value vs. none
. |
---|
Active, n=22 (21 mo.) | 7.0 | 0.0003 | 79.8 | 0.0009 | 19.0 | 0.06 |
Inactive, n=23 (31mo.) | 5.5 | 0.02 | 99.1 | 0.0005 | 8.4 | 0.21 |
None, n=12 (27 mo.) | 3.0 | | 260.5 | | 6.1 | |
Healthy, n=33 (no HSCT) | 1.9 | 0.003 | 89.5 | 0.0004 | 27.3 | <0.0001 |
Median CD27 expression on B cell subsets in cGVHD
Disease Status
. | CD27 on IgDHiCD38HiB (Pre-GC%)
. | p-value vs. none
. | CD27 on IgDLoCD38Lo B (Memory%)
. | p-value vs. none
. | CD27 on IgDLoCD38Hi (Plasmablast%)
. | p-value vs. none
. |
---|
Active (n=22) | 41.3 | 0.06 | 20.4 | 0.04 | 86.9 | 0.03 |
Inactive (n=23) | 9.7 | 0.42 | 18.4 | 0.06 | 66.4 | 0.23 |
None (n=12) | 4.4 | | 10.9 | | 36.7 | |
Healthy, no HSCT (n=33) | 4.7 | 0.65 | 32.8 | <0.0001 | 40.7 | 0.79 |
Disease Status
. | CD27 on IgDHiCD38HiB (Pre-GC%)
. | p-value vs. none
. | CD27 on IgDLoCD38Lo B (Memory%)
. | p-value vs. none
. | CD27 on IgDLoCD38Hi (Plasmablast%)
. | p-value vs. none
. |
---|
Active (n=22) | 41.3 | 0.06 | 20.4 | 0.04 | 86.9 | 0.03 |
Inactive (n=23) | 9.7 | 0.42 | 18.4 | 0.06 | 66.4 | 0.23 |
None (n=12) | 4.4 | | 10.9 | | 36.7 | |
Healthy, no HSCT (n=33) | 4.7 | 0.65 | 32.8 | <0.0001 | 40.7 | 0.79 |
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal